All Stories

  1. OSU-6162, a Sigma1R Ligand in Low Doses, Can Further Increase the Effects of Cocaine Self-Administration on Accumbal D2R Heteroreceptor Complexes
  2. On the G Protein-Coupled Receptor Neuromodulation of the Claustrum
  3. Attenuation of Oxytocin and Serotonin 2A Receptor Signaling through Novel Heteroreceptor Formation
  4. Acute Cocaine Enhances Dopamine D2R Recognition and Signaling and Counteracts D2R Internalization in Sigma1R-D2R Heteroreceptor Complexes
  5. Glutamate heteroreceptor complexes in the brain
  6. Understanding the Role of Adenosine A2AR Heteroreceptor Complexes in Neurodegeneration and Neuroinflammation
  7. Disruption of A2AR-D2R Heteroreceptor Complexes After A2AR Transmembrane 5 Peptide Administration Enhances Cocaine Self-Administration in Rats
  8. Effects of Long-Term Alcohol Drinking on the Dopamine D2 Receptor: Gene Expression and Heteroreceptor Complexes in the Striatum in Rats
  9. Differential activation of arginine-vasopressin receptor subtypes in the amygdaloid modulation of anxiety in the rat by arginine-vasopressin
  10. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer’s disease and levodopa-induced dyskinesia
  11. Cocaine modulates allosteric D2-σ1 receptor-receptor interactions on dopamine and glutamate nerve terminals from rat striatum
  12. Disturbances in the FGFR1-5-HT1A Heteroreceptor Complexes in the Raphe-Hippocampal 5-HT System Develop in a Genetic Rat Model of Depression
  13. Existence of Brain 5-HT1A–5-HT2A Isoreceptor Complexes with Antagonistic Allosteric Receptor–Receptor Interactions Regulating 5-HT1A Receptor Recognition
  14. The neuropeptides Galanin and Galanin(1–15) in depression-like behaviours
  15. Galanin (1-15) enhancement of the behavioral effects of Fluoxetine in the forced swimming test gives a new therapeutic strategy against depression
  16. Cocaine self-administration specifically increases A2AR-D2R and D2R-sigma1R heteroreceptor complexes in the rat nucleus accumbens shell. Relevance for cocaine use disorder
  17. Understanding the Role of GPCR Heteroreceptor Complexes in Modulating the Brain Networks in Health and Disease
  18. IL1R2, CCR2, and CXCR4 May Form Heteroreceptor Complexes with NMDAR and D2R: Relevance for Schizophrenia
  19. Diversity and bias through dopamine D2R heteroreceptor complexes
  20. Existence of muscarinic acetylcholine receptor (mAChR) and fibroblast growth factor receptor (FGFR) heteroreceptor complexes and their enhancement of neurite outgrowth in neural hippocampal cultures
  21. Alterations in ventral and dorsal striatal allosteric A2AR-D2R receptor-receptor interactions after amphetamine challenge: Relevance for schizophrenia
  22. Signaling in dopamine D2 receptor-oxytocin receptor heterocomplexes and its relevance for the anxiolytic effects of dopamine and oxytocin interactions in the amygdala of the rat
  23. Characterization of the interaction between the dopamine D4 receptor, KLHL12 and β-arrestins
  24. Functional role of striatal A2A, D2, and mGlu5 receptor interactions in regulating striatopallidal GABA neuronal transmission
  25. Dopamine D4receptor stimulation prevents nigrostriatal dopamine pathway activation by morphine: relevance for drug addiction
  26. Cocaine self-administration differentially affects allosteric A2A-D2 receptor-receptor interactions in the striatum. Relevance for cocaine use disorder
  27. Purinergic signaling in Parkinson's disease. Relevance for treatment
  28. Multiple D2 heteroreceptor complexes: new targets for treatment of schizophrenia
  29. Galanin (1–15) enhances the antidepressant effects of the 5-HT1A receptor agonist 8-OH-DPAT: involvement of the raphe-hippocampal 5-HT neuron system
  30. Role of iso-receptors in receptor-receptor interactions with a focus on dopamine iso-receptor complexes
  31. FGFR1–5-HT1A Heteroreceptor Complexes: Implications for Understanding and Treating Major Depression
  32. Understanding the Functional Plasticity in Neural Networks of the Basal Ganglia in Cocaine Use Disorder: A Role for Allosteric Receptor-Receptor Interactions in A2A-D2 Heteroreceptor Complexes
  33. Volume transmission and receptor-receptor interactions in heteroreceptor complexes: understanding the role of new concepts for brain communication
  34. Galanin receptor 2-neuropeptide Y Y1 receptor interactions in the dentate gyrus are related with antidepressant-like effects
  35. Heteroreceptor Complexes and their Allosteric Receptor–Receptor Interactions as a Novel Biological Principle for Integration of Communication in the CNS: Targets for Drug Development
  36. The zinc binding receptor GPR39 interacts with 5-HT1A and GalR1 to form dynamic heteroreceptor complexes with signaling diversity
  37. Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5
  38. Enhancement of the FGFR1 signaling in the FGFR1-5-HT1A heteroreceptor complex in midbrain raphe 5-HT neuron systems. Relevance for neuroplasticity and depression
  39. The role of transmitter diffusion and flow versus extracellular vesicles in volume transmission in the brain neural–glial networks
  40. Volume Transmission in Central Dopamine and Noradrenaline Neurons and Its Astroglial Targets
  41. A Role for Galanin N-Terminal Fragment (1–15) in Anxiety- and Depression-Related Behaviors in Rats
  42. Evidence for the existence of FGFR1–5-HT1A heteroreceptor complexes in the midbrain raphe 5-HT system
  43. Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease
  44. On the role of A2A and D2 receptors in control of cocaine and food-seeking behaviors in rats
  45. G-protein-coupled receptor type A heteromers as an emerging therapeutic target
  46. Potential of caveolae in the therapy of cardiovascular and neurological diseases
  47. “Neuro-Semeiotics” and “Free-Energy Minimization” Suggest a Unified Perspective for Integrative Brain Actions: Focus on Receptor Heteromers and Roamer Type of Volume Transmission
  48. Preferential activation by galanin 1–15 fragment of the GalR1 protomer of a GalR1–GalR2 heteroreceptor complex
  49. Neurotensin NTS1-Dopamine D2 Receptor-Receptor Interactions in Putative Receptor Heteromers: Relevance for Parkinson’s Disease and Schizophrenia
  50. Dopamine D1 and D2 receptor immunoreactivities in the arcuate-median eminence complex and their link to the tubero-infundibular dopamine neurons
  51. The impact of receptor–receptor interactions in heteroreceptor complexes on brain plasticity
  52. Information handling by the brain: proposal of a new “paradigm” involving the roamer type of volume transmission and the tunneling nanotube type of wiring transmission
  53. Galanin receptor 2-neuropeptide Y Y1 receptor interactions in the amygdala lead to increased anxiolytic actions
  54. The G Protein-Coupled Receptor Heterodimer Network (GPCR-HetNet) and Its Hub Components
  55. Diversity and Bias through Receptor–Receptor Interactions in GPCR Heteroreceptor Complexes. Focus on Examples from Dopamine D2 Receptor Heteromerization
  56. Dopamine D4 Receptor Counteracts Morphine-Induced Changes in µ Opioid Receptor Signaling in the Striosomes of the Rat Caudate Putamen
  57. Dopamine D2 heteroreceptor complexes and their receptor–receptor interactions in ventral striatum
  58. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes
  59. Understanding the balance and integration of volume and synaptic transmission. Relevance for psychiatry
  60. Dynamic modulation of FGFR1–5-HT1A heteroreceptor complexes. Agonist treatment enhances participation of FGFR1 and 5-HT1A homodimers and recruitment of β-arrestin2
  61. Moonlighting Proteins and Protein–Protein Interactions as Neurotherapeutic Targets in the G Protein-Coupled Receptor Field
  62. Dopamine D2 receptor signaling dynamics of dopamine D2-neurotensin 1 receptor heteromers
  63. Volume transmission and its different forms in the central nervous system
  64. A New Interpretative Paradigm for Conformational Protein Diseases
  65. Bioluminescence Resonance Energy Transfer Methods to Study G Protein-Coupled Receptor–Receptor Tyrosine Kinase Heteroreceptor Complexes
  66. G Protein–Coupled Receptor Heterodimerization in the Brain
  67. On the G-Protein-Coupled Receptor Heteromers and Their Allosteric Receptor-Receptor Interactions in the Central Nervous System: Focus on Their Role in Pain Modulation
  68. G protein-coupled receptor oligomerization and brain integration: Focus on adenosinergic transmission
  69. On the role of volume transmission and receptor–receptor interactions in social behaviour: Focus on central catecholamine and oxytocin neurons
  70. Possible genetic and epigenetic links between human inner speech, schizophrenia and altruism
  71. Molecular determinants of A2AR-D2R allosterism: role of the intracellular loop 3 of the D2R
  72. Fluorescence resonance energy transfer-based technologies in the study of protein–protein interactions at the cell surface
  73. Evidence for the existence of dopamine d2-oxytocin receptor heteromers in the ventral and dorsal striatum with facilitatory receptor–receptor interactions
  74. Integrin triplets of marine sponges in human D2 receptor heteromers
  75. Integrin Triplets of Marine Sponges in Human Brain Receptor Heteromers
  76. Microvesicle and tunneling nanotube mediated intercellular transfer of g-protein coupled receptors in cell cultures
  77. Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome
  78. Extrasynaptic Neurotransmission in the Modulation of Brain Function. Focus on the Striatal Neuronal–Glial Networks
  79. Fibroblast Growth Factor Receptor 1– 5-Hydroxytryptamine 1A Heteroreceptor Complexes and Their Enhancement of Hippocampal Plasticity
  80. On the existence and function of galanin receptor heteromers in the central nervous system
  81. On the origin of the triplet puzzle of homologies in receptor heteromers: toll-like receptor triplets in different types of receptors
  82. On the Origin of the Triplet Puzzle of Homologies in Receptor Heteromers: Immunoglobulin Triplets in Different Types of Receptors
  83. Differential expression of muscarinic acetylcholine receptor subtypes in Jurkat cells and their signaling
  84. Altered trafficking and unfolded protein response induction as a result of M3 muscarinic receptor impaired N-glycosylation
  85. Moonlighting characteristics of G protein-coupled receptors: Focus on receptor heteromers and relevance for neurodegeneration
  86. Agonist-induced formation of FGFR1 homodimers and signaling differ among members of the FGF family
  87. Adenosine receptor containing oligomers: Their role in the control of dopamine and glutamate neurotransmission in the brain
  88. Overproduction of human M3 muscarinic acetylcholine receptor: An approach toward structural studies
  89. Dopamine D4 receptor oligomerization - contribution to receptor biogenesis
  90. On the Existence of a Possible A2A–D2–β-Arrestin2 Complex: A2A Agonist Modulation of D2 Agonist-Induced β-Arrestin2 Recruitment
  91. Muscarinic receptor family interacting proteins: Role in receptor function
  92. Dissecting the Conserved NPxxY Motif of the M3 Muscarinic Acetylcholine Receptor: Critical Role of Asp-7.49 for Receptor Signaling and Multiprotein Complex Formation
  93. Dopamine D2 and D4 receptor heteromerization and its allosteric receptor–receptor interactions
  94. Characterization of the A2AR–D2R interface: Focus on the role of the C-terminal tail and the transmembrane helices
  95. Dopamine D2 and 5-hydroxytryptamine 5-HT2A receptors assemble into functionally interacting heteromers
  96. G protein-coupled receptor oligomerization for what?
  97. The changing world of G protein-coupled receptors: from monomers to dimers and receptor mosaics with allosteric receptor–receptor interactions
  98. The M5 muscarinic acetylcholine receptor third intracellular loop regulates receptor function and oligomerization
  99. Adenosine-Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders
  100. A serine point mutation in the adenosine A2AR C-terminal tail reduces receptor heteromerization and allosteric modulation of the dopamine D2R
  101. Galanin receptor-1 modulates 5-hydroxtryptamine-1A signaling via heterodimerization
  102. Impaired M3 Muscarinic Acetylcholine Receptor Signal Transduction Through Blockade of Binding of Multiple Proteins to its Third Intracellular Loop
  103. Vectors and P64k gene targeting for tandem affinity purification in Neisseria meningitidis